Patient Square Capital LP Q4 2024 Filing

Filed February 14, 2025

Portfolio Value

$267.4B

Holdings

20

Report Date

Q4 2024

Filing Type

13F-HR

All Holdings (20 positions)

#StockSharesValue% PortfolioType
1
ROIVROIVANT SCIENCES LTD
12,480,000$147.6B55.22%
2
LQDALIQUIDIA CORPORATION
1,860,371$21.9B8.18%
3
IM8NINSMED INC
307,167$21.2B7.93%
4
CGEMCULLINAN THERAPEUTICS INC
878,897$10.7B4.00%
5
EYPTEYEPOINT PHARMACEUTICALS
1,410,331$10.5B3.93%
6
NRIXNURIX THERAPEUTICS, INC.
446,296$8.4B3.14%
7
ITCIEURINTRA-CELLULAR THERAPIES INC.
71,990$6.0B2.25%
8
ELVNENLIVEN THERAPEUTICS INC
224,038$5.0B1.89%
9
GONGERON CORPORATION
1,321,268$4.7B1.75%
10
OCULOCULAR THERAPEUTIX, INC.
470,919$4.0B1.50%
11
AGIOAGIOS PHARMACEUTICALS, INC.
121,732$4.0B1.50%
12
PHVSPHARVARIS N V
207,603$4.0B1.49%
13
IRONDISC MEDICINE, INC.
56,400$3.6B1.34%
14
SWTXSPRINGWORKS THERAPEUTICS, INC.
93,137$3.4B1.26%
15
ALLOALLOGENE THERAPEUTICS, INC.
1,489,909$3.2B1.19%
16
MIRMMIRUM PHARMACEUTICALS, INC.
64,900$2.7B1.00%
17
NTLAINTELLIA THERAPEUTICS, INC.
215,981$2.5B0.94%
18
ARVNARVINAS, INC.
86,627$1.7B0.62%
19
SRRKSCHOLAR ROCK HOLDING CORPORATION
32,000$1.4B0.52%
20
CATBUSDASTRIA THERAPEUTICS INC
105,057$939.2M0.35%